Regulation of p53 downstream genes

Seminars in Cancer Biology

Volumn 8, Issue 5, 1998, Pages 345-357

  El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Cancer; Growth arrest; p53; Transcription; Tumor suppressor

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLINE; DNA; DNA BINDING PROTEIN; FAS ANTIGEN; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; DNA DAMAGE; GROWTH DISORDER; MITOSIS INHIBITION; ONCOGENE; PROTEIN DNA BINDING; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0031987277     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1998.0097     Document Type: Article

References (97)

1. 1 El-Deiry WS (1998) Review: the p53 pathway and cancer therapy. The Cancer J 11:229-236.
2. 2. Kubbutat MHG, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303.
3. 3. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
4. 4. Kubbutat MHG, Ludwig RL, Ashcroft M, Vousden KH (1998) Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 18:5690-5698.
5. 5. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee H-W, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
6. 6. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G (1998) The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17:5001-5014.
7. 7. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF (1998) Myc signalling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424-2433.
8. 8. de Stanchina E, McCurrach ME, Zindy F, Shieh S-Y, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW (1998) E1A signalling to p53 involves the p19ARF tumor suppressor. Genes Dev 12:2434-2442.
9. ARF links the tumour suppressors RB and p53. Nature 395:124-125.
10. ARF links the tumour suppressor p53 to Ras. Nature 395:125-126.
11. INGI cooperates with p53 in cell growth control. Nature 391:295-298.
12. 12. Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS (1998) BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713-1721.
13. 13. Carmeliet P, Dor Y, Herbert J-M, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshet E (1998) Role of HIF-1 α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490.
14. 14. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao Z-X, Kumar S, Howley PM, Livingston DM (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 2:405-415.
15. 15. Shieh S-Y, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
16. 16. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee PWK (1998) DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394:700-704.
17. 17. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471-3481.
18. 18. Banin S, Moyal L, Shieh S-H, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-1677.
19. 19. Canman CE, Lim D-S, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-1679.
20. 20. Waterman MJF, Stravridi ES, Waterman JLF, Halazonetis TD (1998) ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genet 19:175-178.
21. 21. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831-2841.
22. 22. Zhang YP, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4A locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.
23. 23. Xu Y, Baltimore D (1996) Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev 10:2401-2410.
24. 24. Cho Y, Gorina S, Jeffre PD, Pavletich NP (1994) Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
25. 25. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831-2841.
26. 26. Resnick-Silverman L, St. Clair S, Maurer M, Zhao K, Manfredi JJ (1998) Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev 12:2102-2107.
27. 27. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nature Genet 1:45-49.
28. 28. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
29. 29. El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B (1995) Topological control of p21(WAF1/CIP1) expression in normal and neoplastic tissues. Cancer Res 55:2910-2919.
30. 30. El-Deiry WS (1998) p21/p53, cellular growth control and genomic integrity, in Current Topics in Microbiology and Immunology (Reed SI, Vogt PK, eds), pp. 121-137. Springer-Verlag, Berlin.
31. 31. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P (1995) Mice lacking p21(CIP1/WAF1) undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
32. 32. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ (1995) Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557
33. 33. Waldman T, Kinzler KW, Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55:5187-5190.
34. 34. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B (1997) 14-3-3 σ is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3-11.
35. 35. Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, Fornace AJ Jr (in press) Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene.
36. 36. Utrera R, Collavin L, Lazarevic D, Delia D, Schneider C (1998) A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. EMBO J 17:5015-5025.
37. 37. Zhan QM, Chen IT, Antinore MJ, Fornace AJ (1998) Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding. Mol Cell Biol 18:2768-2778.
38. 38. Miyashita T, Krajewski S, Krajewski M, Wang HG, Lin HK, Hoffman B, Lieberman D, Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene 9:1799-1805.
39. 39. Owen-Scaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang W-W, Kruzel E, Radinsky R (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15:3032-3040.
40. 40. Wu GS, Burns TF, McDonald ER III, Jiang W, Meng R, Krantz ID, Kao G, Gan D-D, Zhou J-Y, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet 17:141-143.
41. 41. Polyak, K, Xia Y, Zwier JK, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389:300-305.
42. 42. Buckbinder L, Talbott R, Velascomiguel S, Takenaka I, Faha B, Seizinger BR, Kley N (1995) Induction of the growth inhibitor IGF-binding protein-3 by p53. Nature 377:646-649.
43. 43. Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A, Oren M (1997) A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 16:4384-4392.
44. 44. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in-vivo with a conserved homolog, bax, that accelerates programmed cell-death. Cell 74:609-619.
45. 45. Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay T, Jansen B, Borner C (1998) Bcl-2 prolongs cell survival after bax-induced release of cytochrome c. Nature 391:496-499.
46. 46. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Eng TI, Jones DP, Wang X (1997) Prevention of apoptosis by bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129-1132.
47. 47. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES (1998) Autoactivation of procaspase-9 by APAF-1-mediated oligomerization. Mol Cell 1:949-957.
48. 48. Han JH, Sabbatini P, Perez D, Rao L, Modha D, White E (1996) The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting bax protein. Genes Dev 10:461-477.
49. 49. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
50. 50. Knudson CM, Tung KSK, Tourtellotte WG, Brown GAJ, Korsmeyer SJ (1995) Bax-deficient mice with lymphoid hyperplasia and male germ-cell death. Science 270:96-99.
51. 51. Yin CY, Knudson CM, Korsmeyer SJ, VanDyke T (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385:637-640.
52. 52. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M (1997) Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 275:967-969.
53. 53. McCurrach ME, Connor TMF, Knudson CM, Korsmeyer SJ, Lowe SW (1997) Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 94:2345-2349.
54. 54. Nagata S (1997) Apoptosis by death factor. Cell 88:355-365.
55. 55. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366.
56. 56. Fuchs EJ, McKenna KA, Bedi A (1997) p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32 beta. Cancer Res 57:2550-2554.
57. 57. Yeh W-C, de la Pompa JL, McCurrach ME, Shu H-B, Elia AJ, Shahinian A, Ng M, Wakeham A, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV, Mak TW (1998) FADD: Essential for embryo development and signalling from some, but not all, inducers of apoptosis. Science 279:1954-1958.
58. 58. Bennett M, Macdonald K, Chan S-W, Luzio JP, Simari R, Weissberg P (1998) Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282:290-293.
59. 59. Ashkenazi A, Dixit VM (1998) Death receptors: signalling and modulation. Science 281:1305-1308.
60. 60. Pan G, Ni J, Wei Y-F, Yu G-l, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818.
61. 61. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signalling and decoy receptors. Science 277:818-821.
62. 62. Pai SI, Wu GS, Ozoren N, Wu L, Jen J, Sidransky D, El-Deiry WS (1998) Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58:3513-3518.
63. 63. Yin Y, Terauchi Y, Solomon GG, Aizawa S, Rangarajan PN, Yazaki Y, Kadowaki T, Barrett JC (1998) Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature 391:707-710.
64. 64. Rajah R, Valentinis B, Cohen P (1997) Insulin like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem 272:12181-12188.
65. 65. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584.
66. 66. Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K, Yoshida S, Ono M, Kuwano M, Nakamura Y, Tokino T (1997) A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15:2145-2150.
67. 67. Van Meir EG, Polverini PJ, Chazin VR, Huang HJS, Detribolet N, Cavenee WK (1994) Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet 8:171-176.
68. 68. Okamoto K, Beach D (1994) Cyclin-G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 13: 4816-4822.
69. 69. Furuhata T, Tokino T, Urano T, Nakamura Y (1996) Isolation of a novel GPI-anchored gene specifically regulated by p53; correlation between its expression and anti-cancer drug sensitivity. Oncogene 13:1965-1970.
70. 70. Fiscella M, Zhang H-L, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O'Connor PM, Appella E (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 94:6048-6053.
71. 71. Lehar SM, Naeht M, Jacks T, Vater CA, Chittenden T, Guild BC (1996) Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells. Oncogene 12: 1181-1187.
72. 72. Kato MV, Sato H, Nagayoshi M, Ikawa Y (1997) Upregulation of the elongation factor-1 alpha gene by p53 in association with death of an erythroleukemia cell line. Blood 90: 1373-1378.
73. 73. Wales MM, Biel MA, El-Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB (1995) p53 activates expression of HIC-1, a new candidate tumor-suppressor gene on 17p13.3. Nature Med 1:570-577.
74. 74. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB (1997) HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 57: 1678-1681.
75. 75. Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA, Lee SW (1998) Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res 58:4439-4444.
76. 76. Takei Y, Ishikawa S, Tokino T, Muto T, Nakamura Y (1998) Isolation of a novel TP53 target gene from a colon cancer cell line carrying a highly regulated wild-type TP53 expression system. Genes Chrom Cancer 23:1-9.
77. 77. Wu GS, Saftig P, Peters C, El-Deiry WS (1998) Potential role for Cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 16:2177-2183.
78. 78. VarmehZiaie S, Okan I, Wang YS, Magnusson KP, Warthoe P, Strauss M, Wiman KG (1997) Wig-1, a new p53-induced gene encoding a zinc finger protein. Oncogene 15: 2699-2704.
79. 79. Ginsberg D, Mechta F, Yaniv M, Oren M (1991) Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88:9979-9983.
80. 80. Kley N, Chung RY, Fay S, Loeffler JP, Seizinger BR (1992) Repression of the basal c-fos promoter by wild-type p53. Nuc Acids Res 20:4083-4087.
81. 81. Santhanam U, Ray A, Sehgal PB (1991) Repression of the interleukin-6 gene promoter by p53 and the retinoblastoma susceptibility gene-product. Proc Natl Acad Sci USA 88: 7605-7609.
82. 82. Moberg KH, Tyndall WA, Hall DJ (1992) Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial-cell line. J Cell Biochem 49:208-215.
83. 83. Webster NJG, Resnik JL, Reichart DB, Strauss B, Haas M, Seely BL (1996) Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res 56:2781-2788.
84. 84. Pesch J, Brehm U, Staib C, Grummt F (1996) Repression of interleukin-2 and interleukin-4 promoters by tumor suppressor protein p53. J Interferon Cytokine Res 16:595-600.
85. 85. Miu X, Miller CW, Koeffle PH, Berk AJ (1993) The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol 13:3291-3300.
86. 86. Bargonetti J, Chicas A, White D, Prives C (1997) p53 represses Sp1 DNA binding and HIV-LTR directed transcription. Cell Mol Biol 43:935-949.
87. 87. Bhat MK, Yu CL, Yap N, Zhan QM, Hayashi Y, Seth P, Cheng SY (1997) Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signalling. J Biol Chem 272: 28989-28993.
88. 88. Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH, Cheng SY (1997) The tumor suppressor p53 is a negative regulator of estrogen receptor signalling pathways. Biochem Biophys Res Comm 239:617-620.
89. 89. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L (1998) p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273: 11995-11998.
90. 90. Fritsche M, Mundt M, Merkle C, Jahne R, Groner B (1998) p53 suppresses cytokine-induced, Stat5 mediated activation of transcription. Mol Cell Endocrinol 143: 143-154.
91. 91. Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res 54:3131-3135.
92. 92. Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, El-Deiry WS, Fuchs EJ, Bedi A (1998) p53-mediated repression of nuclear factor-kappa B RelA via the transcriptional integrator p300. Cancer Res 58:4531-4536.
93. 93. Agoff SN, Hou J, Linzer DI, Wu B (1993) Regulation of the human hsp70 promoter by p53. Science 259:84-87.
94. 94. Chin KV, Ueda K, Pastan I, Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462.
95. 95. Murphy M, Hinman A, Levine AJ (1996) Wild-type p53 negatively regulates the expression of microtubule-associated protein. Genes Dev 10:2971-2980.
96. 96. Guenal I, Risler Y, Mignotte B (1997) Down-regulation of actin genes precedes microfilament network disruption and actin cleavage during p53-mediated apoptosis. J Cell Sci 110:489-495.
97. 97. Shaulian E, Haviv I, Shaul Y, Oren M (1995) Transcriptional repression by the C-terminal domain of p53. Oncogene 10:671-680.